A meta-analysis by Chen et al. [12], including prospective studies of taxane-treated breast, lung, ovarian, gastric, and head/neck cancer patients, reported better survival in ABCB1 rs1128503 variant carriers, consistent with our findings [12]. This evidence concerns the gene ABCB1 and head and neck cancer.